Active substances
Aluminium hydroxide + Magnesium hydroxide + Simeticone
- SFDA 10
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| MAALOX PLUS SUSP. | 45,40,5 mg,mg,mg | Oral suspension · Oral use | 1 Bottle | SAR 9.10 | Generic · OTC | sanofi-aventis | Valid |
| MOXAL PLUS Suspension | 215,80,25 mg,mg,mg | Oral suspension · Oral use | 1 Bottle | SAR 5.65 | Generic · OTC | Gulf Pharmaceutical Industries (Julphar) | Valid |
| DI-GEL LIQUID | 282, 85, 25 mg | Oral suspension · Oral use | 1 Bottle | SAR 5.85 | NCE · OTC | SCHERING-PLOUGH | Withdrawn by MAH · Not Marketed |
| DI-GEL TABLETS | 282, 85, 26 mg | Tablet · Oral use | 60 Bottle | SAR 7.80 | NCE · OTC | SCHERING-PLOUGH | Withdrawn by MAH · Not Marketed |
| DI-GEL TABLETS | 282, 85, 27 mg | Tablet · Oral use | 30 Bottle | SAR 4.20 | NCE · OTC | SCHERING-PLOUGH | Withdrawn by MAH · Not Marketed |
| MEDACID PLUS CHEWABLE TABLET | 200, 200, 25 mg | Chewable tablet · Oral use | 30 Tablet Container | SAR 3.80 | Generic · OTC | MEDPHARMA PHARMACEUTICAL & CHEMICAL INDUSTRIES | Withdrawn by MAH · Not Marketed |
| MEDACID PLUS SUSPENSION | 45, 40, 5 mg/ml | Oral suspension · Oral use | 1 Bottle | SAR 6.65 | Generic · OTC | MEDPHARMA PHARMACEUTICAL & CHEMICAL INDUSTRIES | Withdrawn by MAH · Not Marketed |
| NOVAGEL PLUS SUSPENSION | 73, 60, 6 mg/ml | Suspension · Oral use | 1 Bottle | SAR 5.15 | Generic · OTC | APM | Withdrawn by MAH · Not Marketed |
| RIALOX PLUS | 225, 200, 20 mg | Chewable tablet · Oral use | 30 Blister | SAR 7.75 | Generic · OTC | RIYADH PHARMA | Withdrawn by MAH · Not Marketed |
| RIALOX PLUS | 45, 40, 5 mg/ml | Oral suspension · Oral use | 1 Bottle | SAR 9.70 | Generic · OTC | RIYADH PHARMA | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
DYSPEPSIA; TUBERCULOSIS-SUPPORTIVE CARE
Components
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.